Perrigo Company PLC (PRGO): Price-to-Sales Ratio

Corporate company logo of Perrigo Company PLC (PRGO)

The average P/S of Perrigo Company plc (PRGO) demonstrates the impact of personnel stability among chemical technologists on cash flows, with the 0.60 mark reflecting the latest data. This trend is driven by trade barriers and logistical disruptions in global supply chains. Simultaneously, management is optimizing the corporate structure by divesting non-core assets to increase margins within the consumer healthcare sector.

PRGO perrigo.com Price-to-Revenue Ratio (07/04/2022 - 11/13/2026)

Analytical breakdowns for Perrigo Company (PRGO)

- share price and consensus valuation forecast:
Price Performance Chart perrigo.com|PRGO - Price Target Chart
- stock exchange capitalization data:
Market Valuation Perrigo Company|PRGO - Enterprise Value
- balance sheet net asset value indicators:
Net Asset Value per Share Perrigo|PRGO - Company Book Value|Market Value to Book Value perrigo.com|PRGO - Aggregate Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Perrigo Company plc|PRGO - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Perrigo Corp|PRGO - Company Aggregate Debts|Debt to Net Assets Perrigo Company|PRGO - Company Long-Term Debt|Short-Term Debt Perrigo|Intermediate Coverage Ratio perrigo.com
- earnings and multiples data:
PRGO - Net Profit|Future Profit Perrigo Company plc|PRGO - Price to Earnings Ratio|Projected Price to Earnings Ratio Perrigo Company PLC|PRGO - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Perrigo Company|PRGO - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Perrigo|PRGO - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth perrigo.com|PRGO - Earnings per share growth in current year|Projected earnings per share growth rate for next year Perrigo Company plc
- total revenue and sales volume data:
PRGO - Company Sales|Company Expected Sales Volume perrigo.com|PRGO - Market Cap to Revenue|Forward Price to Sales Perrigo Company
General company analysis:Perrigo Company plc
Finished products of Perrigo Company plc

The P/S multiple reflects the market value of a business relative to its generated revenue, allowing for the determination of asset overvaluation by comparing market capitalization with actual sales. By analyzing current P/S dynamics, an investor can identify undervaluation points for Perrigo Company plc (PRGO), where growth potential is supported by leadership in the store-brand pharmaceutical segment and the consumer shift toward affordable generic alternatives to brand-name drugs.

Competitors of Perrigo Company plc

HLN (haleon.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kenvue KVUE|VRNA (Verona Pharma PLC) - Price-to-Sales Ratio|Jyong Biotech Corp - P/S Multiple|Price to Sales Ligand Corp|Amneal Pharmaceuticals (AMRX) - Price-to-Revenue Ratio|alvotech.com - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Liquidia|GLPG: Market Capitalization-to-Revenue Ratio|P/S Multiple ANIP|Price-to-Revenue Coefficient Afrezza|P/S Multiple AMPH (Amphastar Pharmaceuticals)|Price-to-Revenue Multiple pacira.com|SPRY - Price-to-Revenue Ratio|Price to Sales Theravance Biopharma Inc|AQST (Aquestive Pharma) - Market Cap to Revenue|scPharmaceuticals - Market Capitalization-to-Revenue Ratio|TECX (Tectonic Therapeutic Inc.) - P/S Multiple|Market Cap to Revenue tonixpharma.com (TNXP)|Price-to-Revenue Ratio China SXT Pharmaceuticals (SXTC)|EPRX - Price to Sales|Price-to-Revenue Ratio BioHarvest BHST|EXOZ - Market Cap to Revenue|ORMP - Price-to-Revenue Ratio|Price-to-Sales Ratio ENTX|HYFT: P/S Multiple|ABVC BioPharma Inc. (ABVC) - P/S Multiple|Price-to-Revenue Ratio Cumberland Pharma|Market Cap to Revenue Ratio QNTM (Quantum BioPharma Corp)|Market Cap to Revenue FGEN (FibroGen, Inc.)|TELO - Price to Sales|Rani Therapeutics Holdings, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio SNYR|RLYB - Price-to-Revenue Ratio|Price-to-Sales Ratio LEXX|Pulmatrix, Inc. (PULM) - Price-to-Revenue Ratio|PTHL (Pheton Holdings) - Price-to-Revenue Ratio|APM (Aptorum Group Ltd) - P/S Multiple|Market Cap to Revenue Lyra Therapeutics Inc. (LYRA)|Price-to-Revenue Ratio Impact BioMedical (IBO)|TNFA: Price-to-Sales Ratio|Price-to-Revenue Ratio cbdMD YCBD|Market Capitalization-to-Revenue Ratio PRFX|Auris Medical - P/S Multiple|Price-to-Revenue Multiple Lipella Pharmaceuticals Inc (LIPO)|Optinose (OPTN) - Price-to-Revenue Ratio|Price to Sales Pieris Pharma (PIRS)|Price-to-Revenue Ratio Procaps Group S.A.|petrospharma.com - Price-to-Sales Ratio|P/S Multiple QLI|SLRN (Acelyrin Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple TFFP (TFF Pharma)